Infusion of apolipoprotein A-I (apoA-I) to increase cholesterol efflux capacity does not improve outcomes in patients with acute myocardial infarction (MI). This finding from the AEGIS-II trial was presented at ACC.24.

A total of 18,219 patients with acute MI, multivessel coronary artery disease and additional cardiovascular risk factors were randomly assigned to receive four weekly infusions of 6 g of CSL112 or matching placebo. After 90 days of follow-up, the rate of the primary end point (a composite of MI, stroke or cardiovascular death) was not significantly different between the two groups (4.8% versus 5.2%; HR 0.93, 95% CI 0.81–1.05, P = 0.24). There was also no significant difference between the groups at 180 days and 365 days of follow-up.